Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Glioma 1Glioblastoma 1

Interventions

Magnetic Resonance Spectroscopy 5Temozolomide 2Immunotherapy, Adoptive 2Aminolevulinic Acid 2thymoglobulin 1temsirolimus 1poly ICLC 1pembrolizumab 1pazopanib 1orludodstat 1keyhole-limpet hemocyanin 1gallium Ga 68 dotatate 1fludarabine phosphate 1fluciclovine F-18 1dexamethasone acetate 1dexamethasone 21-phosphate 1cixutumumab 1carbon-11 acetate 1cabazitaxel 1bicalutamide 1azeliragon 1auricularum 1atezolizumab 1abemaciclib 1Valproic Acid 1Trail Making Test 1Topotecan 1Thiotepa 1Tacrolimus 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Glioma × Adjuvants, Immunologic × Clear all
NCT02754362 2020-01-13

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

NYU Langone Health

Phase 2 Withdrawn
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡